On or around 04/05/2017 (Notice of voluntarily dismissal)
Filing Date: January 06, 2017
According to the law firm press release, TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematological malignancies and autoimmune diseases: (i) TG-1101 (ublituximab), a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes; and (ii) TGR-1202, an orally available PI3K delta inhibitor for various hematologic malignancies.
Throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business and operations. Specifically, Defendants made false and/or misleading statements and/or omitted material information concerning the GENUINE Phase III trial, assuring investors it was a “best-in-class treatment” that would be “successful” and “offer patients a novel chemo-free treatment option.” As a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.
This case was voluntarily dismissed on April 5, 2017.
Company & Securities Information
Defendant: TG Therapeutics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TGTX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
John Lyon, et al. v. TG Therapeutics, Inc., et al.
COURT: S.D. New York
DOCKET #: 17-CV-00112
JUDGE: Hon. Victor Marrero
DATE FILED: 01/06/2017
CLASS PERIOD START: 09/15/2014
CLASS PERIOD END: 10/12/2016
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Levi & Korsinsky (Stamford) 733 Summer Street, Suite 304, Levi & Korsinsky (Stamford), CT 06901 203-992-4523 ·
First Identified Complaint (FIC) Filings:
Complaint for Violations of the Federal Securities Laws
Order Granting the Samee Movants' Motion for: (1) Consolidation of the Actions; (2) Appointment as Lead Plaintiffs; and (3) Approval of their Selection of Levi & Korsinsky LLP as Lead Counsel
Notice of Voluntary Dismissal Without Prejudice
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available